Biotie Therapies - Changes board/management/auditors

Change in Biotie management

BIOTIE THERAPIES CORP.           STOCK EXCHANGE RELEASE    17 September 2012 at
9:00 a.m.

Change in Biotie management

Biotie's chief financial officer (CFO) Panu Miettinen is leaving the company
from 1(st) November 2012 to pursue other interests. Kristian Rantala (36), M.Sc.
(Econ), Vice President, Finance based in Finland has been nominated as the
interim CFO. Kristian has been with Biotie for altogether two years and has
previously held senior financial controller and controller positions at Winwind
and Fortum.

The company has started a search for a new CFO.

In Turku, 17 September 2012

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:
Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com
www.biotie.com

DISTRIBUTION:
NASDAQ OMX Helsinki Ltd
Main Media

About Biotie

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease,
Alzheimer's disease and other cognitive disorders, alcohol and drug dependence
(addiction) and post traumatic stress disorder), and inflammatory and fibrotic
liver disease. The company has a strong and balanced development portfolio with
several innovative small molecule and biological drug candidates at different
stages of clinical development. Biotie's products address diseases with high
unmet medical need and significant market potential.

Biotie has a strategic collaboration with UCB Pharma S.A. covering tozadenant
for Parkinson's disease. The Marketing Authorization Application for Biotie's
most advanced product, SelincroTM (nalmefene) for alcohol dependence was filed
in the EU by our partner H. Lundbeck A/S and was accepted for review by the
European Medicines Agency in December 2011. Biotie shares are listed on NASDAQ
OMX Helsinki Ltd.


[HUG#1641425]